Search
foscarbidopa/foslevodopa; levodopa/carbidopa phosphate (Vyalev)
Indications:
- continuous subcutaneous drug treatment for Parkinson's disease (FDA-approved Oct 2024)
Dosage:
- delivered subcutaneously via a continuous-delivery infusion pump
Clinical significance:
- may increase "on" time without increasing dyskinesia [2]
Adverse effects:
- infusion-site erythema (27%)
- pain (26%)
- cellulitis (19%); catheter-site & infusion-site cellulitis uncommon [[2]
- edema (12%) [2]
General
pharmacologic combination
References
- Rosebraugh M et al.
Foslevodopa/foscarbidopa: A new subcutaneous treatment for Parkinson's disease.
Ann Neurol 2021 Mar 26; [e-pub].
PMID: 33772855
https://onlinelibrary.wiley.com/doi/10.1002/ana.26073
- Soileau MJ et al.
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients
with advanced Parkinson's disease: A randomised, double-blind, active-controlled,
phase 3 trial.
Lancet Neurol 2022 Dec; 21:1099
PMID: 36402160
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00400-8/fulltext
Components
foscarbidopa; carbidopa phosphate
foslevodopa; levodopa phosphate